J2KBIO Valuation

Q: What is the Fair Price of A420570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A420570 (₩9510) is trading below our estimate of [[fair value]] (₩83396.33)

Is A420570 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A420570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A420570 (₩9510) is trading below our estimate of fair value (₩83396.33)

Significantly Below Fair Value: A420570 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A420570?

Key metric: As A420570 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A420570. This is calculated by dividing A420570's market cap by their current revenue.
What is A420570's PS Ratio?
PS Ratio	1.6x
Sales	₩34.71b
Market Cap	₩54.34b

A420570 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	7.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A420570's PS Ratio compare to its peers?

The above table shows the PS ratio for A420570 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	21.9x
A298060 SCM Lifescience	42.9x	n/a	₩38.2b
A263050 Eutilex.Co.Ltd	24.8x	n/a	₩75.2b
A304840 PeopleBio	17.8x	n/a	₩79.5b
A168330 Naturalendo Tech	2x	n/a	₩44.6b
A420570 J2KBIO	1.6x	38.3%	₩54.3b

Price-To-Sales vs Peers: A420570 is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (21.9x).

Price to Sales Ratio vs Industry

How does A420570's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.8x	34.7%
A420570 J2KBIO	1.6x	38.3%	US$38.91m
A006280 GC Biopharma	1x	9.0%	US$1.15b
A096530 Seegene	2.7x	15.7%	US$765.97m

26 Companies		Estimated Growth	Market Cap
Industry Avg.	8.8x	73.4%
A420570 J2KBIO	1.6x	n/a	US$38.91m

No more companies

Price-To-Sales vs Industry: A420570 is good value based on its Price-To-Sales Ratio (1.6x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A420570's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A420570 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.6x
Fair PS Ratio	4.7x

Price-To-Sales vs Fair Ratio: A420570 is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.3%

-17.5%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%

Ildong Pharmaceutical

₩340.2b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,180.00

-1.0%

-28.7%